Saama is pleased to continue our Clinical Trial Excellence for Tomorrow and Beyond blog series, each installment of which will be authored by one of our six new Clinical Board of Advisor members. This week, Stephen Cunningham, M.D., President, SRC Pharma Consult; former Chief Scientific Officer and Head of U.S. Clinical Development, Medical Affairs and Evidence-Based Medicine, Novartis, discusses the types of clinical development challenges and opportunities big pharma will face as the 21st century progresses.
Clinical development still relies on fragmented technology infrastructure circa 1990’s. Relatively speaking, we are still in the “Industrial Age” regarding the use of technology to transform clinical drug development.